Table 4: Median PFS and 95% confidential intervals within CMS subtypes and low and high IPS subgroups in various populations received different therapeutics.
RAS wild type treated with cetuximab n = 94 |
RAS wild type treated with bevacizumab n = 43 |
RAS wild type treated with chemotherapy alone n = 51 |
||||
mPFS (95% CI) |
P |
mPFS (95% CI) |
P |
mPFS (95% CI) |
P |
|
CMS1/3/4 |
5.033 (3.092-6.975) |
0.060 |
7.033 (4.153-9.914) |
0.319 |
9.133 (4.106-14.160) |
0.596 |
CMS2 |
9.767 (5.944-9.989) |
11.567 (10.055-13.078) |
10.267 (4.460-16.074) |
|||
Low IPS |
5.333 (2.629-8.038) |
0.004 |
8.333 (6.863-9.803) |
0.767 |
21.000 (0.000-43.888) |
0.413 |
High IPS |
8.033 (6.055-10.012) |
10.533 (9.032-12.035) |
9.133 (6.712-11.554) |